LU90591I2 - Enbrel-etanercept - Google Patents

Enbrel-etanercept

Info

Publication number
LU90591I2
LU90591I2 LU90591C LU90591C LU90591I2 LU 90591 I2 LU90591 I2 LU 90591I2 LU 90591 C LU90591 C LU 90591C LU 90591 C LU90591 C LU 90591C LU 90591 I2 LU90591 I2 LU 90591I2
Authority
LU
Luxembourg
Prior art keywords
enbrel
etanercept
tnf receptors
dnas
products
Prior art date
Application number
LU90591C
Other languages
English (en)
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90591(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of LU90591I2 publication Critical patent/LU90591I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
LU90591C 1989-09-11 2000-05-31 Enbrel-etanercept LU90591I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40537089A 1989-09-11 1989-09-11
US42141789A 1989-10-13 1989-10-13
US07/523,635 US5395760A (en) 1989-09-05 1990-05-10 DNA encoding tumor necrosis factor-α and -β receptors

Publications (1)

Publication Number Publication Date
LU90591I2 true LU90591I2 (fr) 2000-07-31

Family

ID=27410621

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90591C LU90591I2 (fr) 1989-09-11 2000-05-31 Enbrel-etanercept

Country Status (9)

Country Link
US (2) US5395760A (fr)
EP (1) EP0418014B1 (fr)
AT (1) ATE131871T1 (fr)
DE (2) DE10075011I2 (fr)
DK (1) DK0418014T3 (fr)
ES (1) ES2080809T4 (fr)
GR (1) GR3019333T3 (fr)
LU (1) LU90591I2 (fr)
NL (1) NL300008I2 (fr)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479632B1 (en) 1988-09-12 2002-11-12 Yeda Research And Development Co. Ltd. Tumor necrosis factor inhibitory protein and its purification
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
ATE289350T1 (de) * 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
US7264944B1 (en) * 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6232446B1 (en) 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
ATE119942T1 (de) * 1989-05-18 1995-04-15 Yeda Res & Dev Tumor-nekrosefaktor-bindungsprotein ii, seine reinigung und spezifische antikörper.
US6262239B1 (en) 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
JP3443119B2 (ja) * 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US6448380B2 (en) 1989-08-07 2002-09-10 Peptech Limited Tumor necrosis factor antibodies
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
DE10399023I2 (de) * 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
GB2246569A (en) * 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
US20030064480A1 (en) * 1990-06-28 2003-04-03 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
DK0835939T3 (da) * 1990-06-28 2006-03-13 Sanofi Aventis Deutschland Fusionsproteiner med andele af immunglobulin, deres fremstilling og anvendelse
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
ATE171471T1 (de) * 1991-03-29 1998-10-15 Immunex Corp Isolierte virale proteine als cytokinantagonisten
CA2585487A1 (fr) * 1991-04-17 1992-10-29 Medarex Inc. Polypeptides hydrosolubles ayant une haute affinite pour les interferons .alpha. et .beta.
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993007863A1 (fr) * 1991-10-15 1993-04-29 Mullarkey Michael F Procedes et compositions servant a traiter des reactions allergiques
AU671116B2 (en) * 1992-03-30 1996-08-15 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
JPH07509223A (ja) * 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
US20050260201A1 (en) * 1993-01-29 2005-11-24 Centocor, Inc. Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
CA2125763C (fr) * 1993-07-02 2007-08-28 Maurice Kent Gately Homodimere p40 de l'interleukine-12
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US6579697B1 (en) * 1995-05-11 2003-06-17 Yeda Research And Development Co. Ltd. Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
US5741667A (en) * 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5708142A (en) * 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US7094564B1 (en) 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7078493B1 (en) 1995-03-15 2006-07-18 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like genes
US8110659B1 (en) 1995-03-15 2012-02-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like genes
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7070783B1 (en) * 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
ZA966663B (en) * 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
US6410252B1 (en) 1995-12-22 2002-06-25 Case Western Reserve University Methods for measuring T cell cytokines
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
WO1997033904A1 (fr) * 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Recepteurs contenant un domaine de mort cellulaire
US7357927B2 (en) * 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
WO1997034616A1 (fr) * 1996-03-18 1997-09-25 Medical Science Systems, Inc. Procede de traitement des maladies du periodonte
US5912141A (en) * 1996-05-22 1999-06-15 President & Fellows Of Harvard College Nucleic acids encoding tumor virus susceptibility genes
ES2278390T3 (es) * 1996-05-23 2007-08-01 The Scripps Research Institute Sistema de presentacion de antigenos de clase ii de cmh y procedimientos de activacion de linfocitos t cd4+.
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US5939281A (en) * 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
JP2001502912A (ja) * 1996-10-30 2001-03-06 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒト腫瘍壊死因子レセプター―ライク２
CA2270898A1 (fr) 1996-11-06 1998-05-14 The Regents Of The University Of California Enzyme isolee, liberant le recepteur du facteur necrosant des tumeurs, compositions contenant cette enzyme et procede d'utilisation de celles-ci
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
US6930084B1 (en) 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
DE69739375D1 (de) 1996-11-27 2009-06-04 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid-erzeugung
ES2615357T3 (es) 1996-12-06 2017-06-06 Amgen Inc. Terapia de combinación usando un inhibidor de IL-1 para tratar enfermedades mediadas por IL-1
ATE247974T1 (de) 1996-12-06 2003-09-15 Amgen Inc Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1998054201A1 (fr) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Proteine 8 apparentee au recepteur du facteur de necrose tumorale humain
EP1053351A4 (fr) * 1998-01-27 2002-09-25 Millennium Pharm Inc Nouvelles molecules de la superfamille du recepteur du facteur de necrose tumorale et leurs utilisations
US20030180310A1 (en) * 1998-04-29 2003-09-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050265996A1 (en) * 2004-04-30 2005-12-01 Biopheresis Technologies, Inc. Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US7115557B2 (en) * 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
EP1939300A1 (fr) 1999-05-28 2008-07-02 Targeted Genetics Corporation Procédés et compositions pour diminuer le niveau de facteur de nécrose de tumeur (TNF) pour des troubles associés au TNF
JP2003501043A (ja) 1999-05-28 2003-01-14 ターゲティッド ジェネティクス コーポレイション 腫瘍壊死因子（ｔｎｆ）関連障害において、ｔｎｆのレベルを低下させるための方法および組成物
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US7122631B2 (en) * 2000-02-22 2006-10-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU4541101A (en) 2000-03-02 2001-09-12 Xencor Inc Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
WO2002024896A2 (fr) 2000-09-22 2002-03-28 Immunex Corporation Methode de criblage d'agonistes ou d'antagonistes de l'activateur du recepteur de nf-kb
WO2002069232A2 (fr) 2001-02-19 2002-09-06 Merck Patent Gmbh Procede d'identification d'epitopes de lymphocytes t et utilisation dans la preparation de molecules a immunogenicite reduite
US20030040119A1 (en) * 2001-04-11 2003-02-27 The Regents Of The University Of Michigan Separation devices and methods for separating particles
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
WO2003026695A1 (fr) * 2001-09-21 2003-04-03 Genset S.A. Agonistes et antagonistes de cylixine permettant de traiter des troubles du metabolisme
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
MXPA04006053A (es) * 2001-12-21 2005-03-31 Immunex Corp Metodos para purificacion de proteina.
PL215168B1 (pl) 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
WO2003083066A2 (fr) 2002-03-27 2003-10-09 Immunex Corporation Procedes d'augmentation de la production de polypeptides
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1633317A4 (fr) 2003-05-16 2008-08-20 Intermune Inc Ligands des recepteurs des chimiokines synthetiques et leurs methodes d'utilisation
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
HRP20130098T1 (hr) 2003-10-14 2013-02-28 F. Hoffmann - La Roche Ag MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
WO2005040758A2 (fr) * 2003-10-24 2005-05-06 Intermune, Inc. Utilisation de pirfenidone dans des posologies therapeutiques
SG151294A1 (en) 2004-03-23 2009-04-30 Biogen Idec Inc Receptor coupling agents and therapeutic uses thereof
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1789074A4 (fr) * 2004-08-09 2009-08-12 Alios Biopharma Inc Variants de polypeptides synthetiques hyperglycosyles resistants a la protease, formulations orales et leurs procedes d'utilisation
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
US7785834B2 (en) * 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US20070105807A1 (en) * 2005-11-10 2007-05-10 Sazani Peter L Splice switch oligomers for TNF superfamily receptors and their use in treatment of disease
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
WO2007149115A1 (fr) * 2006-06-15 2007-12-27 Targeted Genetics Corporation Procédés de traitement d'articulations cibles dans l'arthrite inflammatoire utilisant des vecteurs aav vectors codant pour un antagoniste du tnf
US20100093829A1 (en) * 2006-07-07 2010-04-15 Gorman James R Methods for preventing, postponing or improving the outcome of spinal device and fusion procedures
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US20090264353A1 (en) * 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
EP2395077A1 (fr) 2006-11-03 2011-12-14 Wyeth LLC Substances inhibant la glycolyse dans une culture de cellules
WO2008097525A2 (fr) 2007-02-05 2008-08-14 Potentia Pharmaceuticals, Inc. Inhibition locale de complément destinée au traitement de troubles induits par le complément
JP5586235B2 (ja) 2007-03-02 2014-09-10 ワイス・エルエルシー ポリペプチドの産生のための細胞培養における銅およびグルタミン酸塩の使用
CA2720610C (fr) 2008-04-07 2016-08-23 Bayer Healthcare Llc Procedes de production recombinante de glycoproteines
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
US8722615B2 (en) * 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
EA031209B9 (ru) 2010-01-15 2021-11-19 Кирин-Эмджен, Инк. Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
ES2739503T3 (es) 2010-07-09 2020-01-31 Bioverativ Therapeutics Inc Moléculas de cadena simple procesables y polipéptidos producidos usándolas
WO2012019160A1 (fr) 2010-08-05 2012-02-09 Amgen Inc. Dipeptides pour améliorer le rendement et la viabilité de cultures cellulaires
CN105177032B (zh) * 2010-09-01 2019-05-10 山东新时代药业有限公司 新型人肿瘤坏死因子受体-Fc融合基因及其产物蛋白
WO2012145682A1 (fr) 2011-04-21 2012-10-26 Amgen Inc. Méthode de culture de cellules de mammifère pour améliorer la production de protéines recombinantes
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
CA2838695C (fr) 2011-07-01 2017-02-14 Amgen Inc. Culture de cellules mammiferes
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
WO2013016220A1 (fr) 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
US20140315187A1 (en) 2011-09-02 2014-10-23 Amgen Inc. Pharmaceutical Product and Method of Analysing Light Exposure of a Pharmaceutical Product
US10350139B2 (en) 2011-10-25 2019-07-16 Corning Incorporated Pharmaceutical glass packaging assuring pharmaceutical sterility
US9474689B2 (en) 2011-10-25 2016-10-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
RS57013B1 (sr) 2012-09-11 2018-05-31 Coherus Biosciences Inc Korektno savijeni etanercept sa visokom čistoćom i odličnim prinosom
US20140199728A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
PT3395423T (pt) 2013-03-14 2023-11-14 Amgen Inc Remoção de ligandos escapados de cromatografia de afinidade
TWI832345B (zh) 2013-03-14 2024-02-11 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707155B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en) 2013-04-24 2017-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
CA2929077C (fr) 2013-10-31 2024-05-28 Amgen Inc. Utilisation de monensine pour reguler la glycosylation de proteines de recombinaison
AU2014376225C1 (en) 2014-01-13 2025-06-05 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
KR102410393B1 (ko) 2014-01-29 2022-06-16 암젠 인크 재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
MY184189A (en) 2014-03-31 2021-03-24 Amgen K A Inc Methods of treating nail and scalp psoriasis
CN106687575B (zh) 2014-06-04 2021-04-30 美国安进公司 用于收获哺乳动物细胞培养物的方法
ES2727380T3 (es) 2014-11-19 2019-10-15 Amgen Inc Cuantificación de resto glucano en glucoproteínas recombinantes
SI3227454T1 (sl) 2014-12-01 2020-06-30 Amgen Inc. Postopek za manipuliranje ravni vsebnosti glikana glikoproteina
KR20170138426A (ko) 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
EP3528787B1 (fr) 2016-10-21 2026-01-07 Amgen Inc. Formulations pharmaceutiques et leurs procédés de préparation
IL307155B2 (en) 2018-05-01 2025-11-01 Amgen Inc Antibodies with modulated glycan profiles
US11952399B2 (en) 2018-12-18 2024-04-09 Amgen Inc. Methods for purifying proteins
CA3241882A1 (fr) 2021-12-29 2023-07-06 Bristol-Myers Squibb Company Generation de lignees de cellules avec site d'integration
WO2025099576A1 (fr) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions et méthodes de traitement de la polyarthrite rhumatoïde

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675285A (en) * 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
JPS61293924A (ja) * 1985-06-23 1986-12-24 Asahi Chem Ind Co Ltd 生理活性物質の受容タンパク
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
EP0325224B1 (fr) * 1988-01-22 1996-07-31 ZymoGenetics, Inc. Procédé de préparation d'analogues de récepteurs sécrétés
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) * 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0394827A1 (fr) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Polypeptides chimériques de CD4-immunoglobuline
DE3922089A1 (de) * 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
ATE119942T1 (de) * 1989-05-18 1995-04-15 Yeda Res & Dev Tumor-nekrosefaktor-bindungsprotein ii, seine reinigung und spezifische antikörper.
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) * 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
DK0835939T3 (da) * 1990-06-28 2006-03-13 Sanofi Aventis Deutschland Fusionsproteiner med andele af immunglobulin, deres fremstilling og anvendelse
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells

Also Published As

Publication number Publication date
ES2080809T3 (es) 1996-02-16
GR3019333T3 (en) 1996-06-30
DE10075011I1 (de) 2003-06-12
EP0418014B1 (fr) 1995-12-20
DE69024291D1 (de) 1996-02-01
EP0418014A1 (fr) 1991-03-20
US5395760A (en) 1995-03-07
DE10075011I2 (de) 2004-08-12
NL300008I1 (nl) 2000-08-01
NL300008I2 (nl) 2000-12-01
ATE131871T1 (de) 1996-01-15
DE69024291T2 (de) 1996-10-31
DK0418014T3 (da) 1996-01-22
USRE36755E (en) 2000-06-27
ES2080809T4 (es) 2012-12-20

Similar Documents

Publication Publication Date Title
LU90591I2 (fr) Enbrel-etanercept
ES2103706T3 (es) Receptores de interleuquina-4.
ES2172502T3 (es) Receptores tipo ii de interleucina 1.
EP0318296A3 (fr) Récepteurs d'interleukine-1
ATE128184T1 (de) Expression des rekombinanten tumor-nekrosisfaktor-bindungsproteins i (tbp-i).
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
DE69016508D1 (de) Interleukin-7-Rezeptoren.
DE3851035D1 (de) Interleukin-7.
DK0494260T3 (da) Receptorer for granulocytkolonistimulerende faktor